Isis Insights 67

7/31/2019 Isis Insights 67

1/28

IiIssue67Spring

12

Also inside: Tumour detection, torque, aviation safety and more

Isis insights

The latest innovations, collaborations

and technology transfer

No-handsnavigation


2/28

Isis Innovation: Information 2

Ii

Ii is produced by Isis Innovation Ltd, the technology transfer company owned bythe University of Oxford. Isis Innovation Ltd 2012 For authorisation to reproduceextracts from this publication please contact Isis. To receive your free copy of Ii,email [email protected] www.isis-innovation.com

Information

03. NewsashThe latest news from Isis

04. Enterprising ConsultancyInsights from Oxford University Consulting

and Isis Enterprise

05. The PortfolioInvestment and spin-out news

Innovation

06. KurarayOxford Innovation Society (OIS) member prole

08. From droplets to tissuesThe synthetic biology research of OIS speaker

Professor Hagan Bayley

10. Patenting valueOIS speaker Dr Lee Chapman, of J.A. Kemp & Co,

discusses patenting

Cardiology

focus

Drug discovery, treatment

and remote monitoring

No-hands

navigation

Autonomous vehicles

for land and sea 1824

No-hands navigation

Issue 67

Contents

Invention

12. Stiff challengeTorque measurement and control

14. Breaking down barriersBrain tumour detection and treatment

16. Pressure pointReinventing pressure regulation

18. Compelling rhythms

Safe antiarrhythmic drug discovery

19. Confronting cardio diseasePrevention and treatment

20. Stethoscope solutionRemote monitoring of the heart

21. Bacterial breakthroughGene-based bacterial identication

22. Let there be light

Improved bandwidth for optical wires

Inspiration

24. No-hands navigationOxford University Consulting and

the Oxford Mobile Robotics Group

26. Optimising IP PortfoliosIsis Enterprise and the Kennedy Trust


3/28

Isis is a research and technology commercialisation companyowned by the University o Oxord.

Research unding uelsinnovation

Innovation comes in many forms, but

almost always as a result of original

research. In the last nancial year the

University of Oxford received more

than 500m in research funding

more than any other UK institution

which supports the breadth and

depth of research activity at Oxford.

It is of course the results of this

research which are commercialisedfor the benet of society by Isis.

So it should be no surprise that the

University is also ranked rst amongst

UK institutions in terms of the number

of mature patents it has led over

recent years according to a recent

report by consultancies PatAnalyse and

TechnologiCa.

Responding to an invitation from the

Science and Technology Commons

Select Committee, Isis contributed to

a governmental study on improving

the commercialisation of research.

We applaud any initiative to support

edgling businesses, we hope to see

greater encouragement for businesses

and people investing for the long

term, and we look forward to sectors

such as healthcare and defence in

the UK enthusiastically adopting new

technologies.

Successesrom Oxord

Spin-out companies from Isis continue

to make the headlines. Yasa Motors,

formed in 2009, is supplying electric

motors to the recently launched

Lola-Drayson Formula 1 racer

(pictured below), which functions as

a technology demonstration platform

showing the potential of an electric

vehicle.

2005 spin-out Oxford Nanopore

announced its game changing

and truly disruptive MinION DNA

sequencer to enthusiastic media

response. The size of a USB memory

stick, it is expected to retail at less

than $900 and is set to revolutionise

the industry.

Featured on the cover of this edition

is a fully autonomous road vehicle,

based on a Bowler Wildcat, being

used by the Mobile Robotics Group to

demonstrate the futuristic concept of

infrastructure-free navigation. Oxford

University Consulting, part of Isis, is

providing access to the information

engineering expertise of this group for

terrestrial and maritime applications

(see page 24).

Early successes rom the IsisSotware Incubator

After just a year the Isis Software

Incubator already has two successful

start-up companies to its name

Pilio (highlighted in Isis Insights 66)

and TheySay, a powerful Sentiment

Analysis tool which launched in

February to widespread interest.

Further successful exits will be

announced over the coming months.

International expansion

Following the establishment of Isis

ofces in China and Spain, we have

now opened an ofce in Japan. Headed

by Kenji Aiba OBE, the ofce in Kyoto

is a focal point of Isis activity to

strengthen business relationships with

industry, investors and academia in

Japan.


NewsashInformation

Photo: Jakob Ebrey Photography


4/28

Enterprising Consultancy

Water in fuel is a serious problem,

especially in aviation where the water

can freeze and block the ow of fuel

to the engine. This was the cause of

the crash of BA38, a Boeing 777, on

its approach to Heathrow from Beijing

in January 2008, according to the UK

Air Accidents Investigations Branch.

Fortunately no one was killed.

The accident was caused by normal

levels of dissolved water condensing

out into the fuel to form an emulsion,

as the bulk fuel temperature dropped

at high altitude. Ice crystals formed

and blocked the fuel lters.

The aviation industry has been aware

of the water in fuel problem since

the 1950s and has addressed this

with several technologies including a

test for undissolved water in aviation

fuel. Tests are typically made on fuel

prior to fuelling the aircraft, and no

subsequent tests are made on the fuel

in the airframe.

To date, there is no standard test

to determine the amount of water

in aviation fuel and there exists an

opportunity to measure the amount of

dissolved water in fuel to determine

when and how much water will

While Oxford University

Consulting (OUC) has yet to

manage the impossible, it did

recently prove it could manage the

near impossible. In consultancy

terms, it was the perfect storm:

a request for urgent help from a

client just before Christmas and

the University closing imminently

for the holidays; the academic

consultant due to go on annualleave immediately after the

Christmas break; a client needing

the deliverables yesterday; an

8 hour time difference to hamper

discussions; and a language barrier

which obscured nuances in the

scope of work.

Working closely with Isis ofce in

China, OUC managed to clarify the

clients precise requirements and a

good working relationship with theacademic consultant along with a

subtle, but effective, negotiation

meant contracts were exchanged

and work started in record time,

demonstrating that miracles, albeit

small ones, do indeed happen at

Christmas time.

Commercial sensitivity precludes

discussion of project details, but

what the story demonstrates is

that OUC is well versed in handling

tricky, multicultural, time-sensitive

negotiations in a manner that does

not compromise the expectations of

the client, protects the interests of

the academic consultant and respects

the processes of the University.

condense out into the fuel during

ight.

The Photonics Research Group at

Aston University has addressed this

market need by developing a test

based on optical bre technology,

with consultancy support from Isis

Enterprise.

The bre is immersed into a

fuel-water mixture and the signal

from the bre changes in the

presence of water. The effect can be

measured using a simple optical setup

and the water concentration can bemeasured within minutes.

Only available test for dissolved

water

Quantitative measurement

Reusable and repeatable


News from Oxford University Consultingand Isis Enterprise

Consulting: the challenges

Sae ying

For more information, please

contact:

Dr Roger Welch

Senior ConsultantIsis Enterprise

T +44 (0)1865 280854

E [email protected]


contact:

Gurinder Punn

Project ManagerOxford University Consulting

T +44 (0)1865 280826

E [email protected]


5/28

The portfolio


The backstory and eclectic applications o a potential spinout with magnetic appeal


contact:

Andrea Alunni

Seed Investment ManagerIsis Innovation

T +44 (0)1865 280843

E [email protected]

Low power magnetic feld

receivers ftted to badgers

(coupled with magnetic felds

above ground) allowed a

researcher from Oxfords

Department of Computer Science

to track the animals in 3D. Dr

Andrew Markham exploited

the unique feature of magnetic

felds to penetrate soil and rock

and, in doing so, he unearthed

groundbreaking applications for

Location Based Services (LBS).

Potential commercial applications

for this technology exist in both the

enterprise and consumer markets. For

example, the capacity to penetrate soil

and rock means that the technology

could be invaluable to the mining

industry. An emergency event, such

as a rock burst or collapse, can isolateportions of underground tunnels,

severing wired communication links and

preventing radio communication. Low

frequency magnetic elds can penetrate

horizontally and vertically regardless of

the tunnel structure and be used both

to establish communication and localise

trapped miners. Recent mining disasters

have highlighted the need for this type

of application.

The technology also has wide ranging

applications in the indoor navigation

consumer market with its unique

ability to penetrate walls and to avoid

the multipath signal effect hampering

some current indoor location

technologies. End users could access

this technology through a smartphone

equipped with specialised magnetic

eld receivers (magnetometers).

Basic magnetometers are already

used in some smartphones, as

sensors for an electronic compass,

for example. The indoor navigation

market is the next LBS frontier,

driven by the increasing ownership of

smartphones and the Location Based

Advertising (LBA) market. In 2015

global smartphone sales are predicted

to reach one billion units and by

2017 it is said that the global LBA

market will be worth $12.8 billion.

Taking advantage of this trend, the

technology could be used to develop

indoor navigation applications to

locate people, places and products

in venues such as airports, shopping

centres, supermarkets, department

stores, museums, exhibition centres,

sports stadiums, overground and

underground train stations and

skyscrapers.

This magnetic technology and its LBS

market potential has been successfully

presented to the University Challenge

Seed Fund for the nancial support of a

commercial prototype.

The location technology, with its

solution based applications, creates

strong opportunities in multiple growth

markets. This, combined with its global

appeal, all add up to a spin-out with

protable prospects and boundless

opportunities. Isis is now looking for

potential investors to support in the

commercialisation of this technology.

The latest spin-outand investmentnews


6/28

Kuraray

Oxord Innovation Society memberKuraray is a chemicals company with

particular expertise in polymerisation and

synthetic chemistry. Kikuo Arimoto, rom

the R&D division, showcases the product

range and plans or the uture.


the thermoplastic elastomer SEPTON

and industrial cleaning agents, and

pharmaceutical intermediates using

isoprene.

Our heat-resistant polyamide resin

GENESTAR exhibits excellent resistance

to abrasion as well as superior chemical

resistance properties and is used in

electronic and automotive components.Demand for GENESTAR has also

grown in LED reector applications

used in TVs equipped with LEDs in the

backlighting device.

Fibres

PVA bre KURALON has a high level of

strength, low elongation, hydrophilic

properties, excellent durability

and is used in various industrial

applications. Man-made leather

CLARINO holds the top place in the

world market, and is in high demand

for shoes, bags and sporting goods.

In addition, the full-scale operation of

a mass-production, environmentally

friendly man-made leather production

system started in 2009.

Diversity

Kuraray also has a water treatment

business, which is expanding, and is

Kuraray is opening new elds of

business using pioneering technology

and contributing to an improved

natural environment and quality of life.

Its range of highly original products,

from a solid technological base, are in

demand in various elds including the

sectors involved in chemicals, resins,

high performance materials, bres,

and medical products.

Chemicals and resins

The synthetic resin POVAL/Mowiol,

polyvinyl alcohol (PVA), is used in a

wide range of products, from bre

sizing agents to polarised lms for

liquid crystal displays.

The PVB polyvinyl butyral resin made

from PVA has adhesive strength and

transparency and is used for glass

interlayers, encapsulation of solar cell

modules and more.

The EVOH (ethylene vinyl alcohol

copolymer) resin EVAL boasts superior

gas-barrier properties and is used for

food packaging and automobile fuel

tanks.

Methacrylic resin, used for optical

components and construction

materials. Kuraray has also developed


7/28


working on waste reduction and the

reuse of valuable materials. Other

business areas for Kuraray include the

manufacture and sale of dental repair

materials.

Looking ahead

Kuraray has a 10-Year Corporate

Vision which guides the long-termdirection in which the Kuraray Group is

heading. It presents a clear image for

growth with the goal of achieving one

trillion Japanese Yen ($12.6 billion)

in net sales as a cornerstone for

establishing Kurarays global presence

as a specialty chemical company.

Kuraray also believes its technological

innovations can provide unique and

effective contributions for resolving

issues threatening our planet

and the living environment. The

company works to achieve harmony

with all of its corporate activities,

the environment and society.

Kuraray is placing emphasis on new

energy-related business, aqua and

environmentally friendly materials. The

group believes that these perspectives

on its role and the contributions it can

make to society are what will make

it possible for Kuraray to achieve

long-term sustainable growth. It plans

to maximize growth capabilities by

leveraging its technical and market

knowledge and harnessing the value

creation potential of the entire group.

In response to the effects of the global

economic crisis Kuraray has instigated

an action plan known as GS-Twins

to rmly establish Kuraray as a

protable specialty company. The plan

combines two main concepts: Green& Safety and Growth & Sustainability,

and has three key initiatives:

improving prot structure

creation and expansion of new

business

acceleration of global strategy for

core businesses

By adopting and executing this plan

Kuraray is preparing a foundation

for sustainable growth, while

contributing to the resolution of issues

that threaten our planet and the

environment.

Image: Polarised LM of liquid crystals


contact:

Kikuo Arimoto

Research and Development

Kuraray Europe GmbHHoechst Industrial Park, 65926

Frankfurt, Germany

T +49 69 305 85906

E [email protected]

www.kuraray.co.jp/en/

Kuraray believesits technological

innovations can

provide unique and

effective contributions

for resolving issues

threatening our

planet and the living

environment.

The Oxford Innovation

Society (OIS) is a

network which exists

to encourage Open

Innovation between

academia, industry

and business.

Many of the worlds

leading companies

are, or have

been, members.

Introductions

and networking

opportunities are

provided for members

to meet leading

academics and otherbusiness leaders, and

Isis provides early

access to

new technology

available to license.

Members can promote

their products and

services to each other

and to the Oxford

ecosystem through

various channels,

including articles such

as this one.


8/28

Isis Innovation: Invention 8

Hagan Bayley is Professor of Chemical

Biology in the Department of

Chemistry at Oxford University. After

starting his academic career in Oxford,

he moved to work at Harvard, MIT,

Columbia and Texas A&M Universities,

before returning to Oxford in 2003.

His lab focuses on the science of

membrane proteins, how they

function and how they can be used

and manipulated to move polymers

from one side of a cell membrane

to the other. This multidisciplinary

work, spanning the interface of

chemistry with biology and physics,

was the foundation for the Oxford

University spinout company Oxford

Nanopore, formed in 2005, which is

using membrane pore technology to

develop a sensing platform for next

generation DNA sequencing. However,

in his talk at the December Oxford

Innovation Society meeting, Professor

Bayley explored a new and exciting

area of research in his lab that of

multisomes.

Multisomes hold particular promise

for synthetic biology, building

articial prototissues for medical

applications. They are assemblies of

lipid-encapsulated droplets formed

by introducing water droplets into

a solution of lipid in oil. Due to

the amphipathic properties of lipid

molecules, they form monolayers

around the water droplets, and

bringing these lipid-coated droplets

together forms an articial lipid

bilayer between them which mimics

cell membranes. Proteins can then

be inserted into the bilayer. By

incorporating different types of

membrane proteins, for example

pumps, channels or pores, which

can be engineered as required,

these droplets can communicate and

interact with each other, forming

functional networks to either mimic

the functioning of real cell membranes

or introduce new properties. These

droplets can therefore be used as

building blocks, generating complexes

of multiple droplets known as

multisomes.

Although this research is still at

an early stage, it has potential

applications in a wide variety of

elds. The type of proteins inserted

determine the properties of the

network and what they could be used

for. Using particular congurations of

ion selective pores allows you to build

miniature electrical circuits withelectrical current owing through

the network carried by ions such

as sodium or potassium and even

miniature biobatteries generating

electrical current, providing an internal

power source for these networks. The

Bayley lab has also experimented

with engineered pump proteins that

respond to light. Inserting these

light-sensitive proteins, such as

bacteriorhodopsin, into the network

From Droplets to

Tissues

Proessor Hagan Bayley, o the

Department o Chemistry, delved into

the world o multisomes and synthetic

biology in his presentation to the Oxord

Innovation Society in December.

Multisomes hold particular promise for synthetic

biology, building articial prototissues for medical

applications.


9/28


allows you to switch on an electrical

circuit simply by shining light on it.

The recent work from the Bayley

lab stabilising these multisomes

and placing them in an aqueous

environment means that they can now

be used in biological and physiological

settings. Suspending or encapsulating

these droplets in gels or aqueousmatrices means that they could be

used to build 2D and 3D articial

cell-like networks a prototissue

where the multicompartment

framework of multisomes mimics a

simple synthetic tissue. These could

then be used in drug-testing of water-

soluble therapeutics or drug-release

systems triggered by external

stimuli (such as temperature or pH).

Multisomes could also potentially be

developed as vehicles for binary drugdelivery, with different molecules

contained in different compartments

such as a prodrug and an enzyme that

activates it. This could be particularly

useful for compounds that you simply

cannot keep in a pill as they have very

short lifetimes of only a few seconds,

yet are very powerful effectors in the

body.

Microuidics techniques allow you to

produce well controlled multisomes

with many compartments suitable

for medical applications. Material

consisting of these complex

multisomes could act like a synthetic

tissue in many respects and potentially


contact:

Professor Hagan Bayley

Department of ChemistryUniversity of Oxford

T +44 (0)1865 285101

E [email protected]

The prototissues

could be used in

drug-testing of water-

soluble therapeutics or

drug-release systems

triggered by externalstimuli.

interface with living tissues, with the

idea of repairing organs or enhancing

their properties.

Further reading:

Villar G, Heron AJ & Bayley H (2011)

Nature Nanotechnology 6(12):803-8.

Formation of droplet networks thatfunction in aqueous environments.

Needham D (2011) Nature

Nanotechnology 6(12):761-2.

Lipid structures: a brief history of

multisomes.


10/28


What is a patent?

As a starting point, it is worth bearing

in mind the purpose of a patent and

how one is obtained. A patent is a deal

between you and the state: you get a

limited monopoly (that typically lasts

for 20 years) in exchange for disclosing

your invention to the world (all patents

will be published). The monopoly means

that you can stop others from using the

invention. The claims in the patent

dene the patented invention and

thereby what others cannot do. A patent

will only be granted for an invention

that is new, involves an inventive step,

and is disclosed in a manner sufciently

clear to be reproduced by a person

skilled in the art.

What to patent

Patent claims are typically directed

to (1) a product, (2) a method of

manufacture or (3) a method of use.

Not all products are patentable, for

instance aesthetic creations (such

as paintings) cannot be patented in

Europe. Also, different countries have

different laws concerning what can

and cannot be patented. For instance,methods of therapeutic treatment

can be patented in the US, whereas

only products for use in therapeutic

treatment can be patented in Europe.

So what should be patented? The key

questions to ask are:

What is commercially interesting to

you and your competitors both now

and in the future?

What is potentially patentable?

What can be covered in the different

countries of interest?

By way of example, the above

evaluation approach has been

undertaken by one of our clients, Oxford

Nanopore Technologies Limited (www.

nanoporetech.com). Oxford Nanopore

was founded in 2005 on the science of

Professor Hagan Bayley during his time

at Texas A&M University. The company

has since expanded its external IP to

include collaborations with a range of

institutions including the University

of Oxford, Harvard and University

of California Santa Cruz (UCSC), to

complement its internally generated IP.

Oxford Nanopores platform technology,

GridION, has been developed for

the single molecule analysis of many

types of analyte including DNA, RNA

and proteins, but the company is best

known for its development of two newtechniques for DNA sequencing using

nanopores: strand sequencing and

exonuclease sequencing.

Oxford Nanopore has broad patent

coverage in many countries: it has

at least 10 of its own international

(PCT) applications and licences or

owns more than 300 patents and

patent applications, including several

families from collaborators such as

Isis Innovation, Harvard and UCSC.Importantly, this broad coverage

crosses all of Oxford Nanopores

technology, including fundamental

nanopore sensing techniques and

chemistry, novel chemistries, novel

electronics and engineering and novel

data analysis techniques. It also

includes future generations of nanopore

technologies such as nanopores

fabricated in synthetic materials like

graphene.

Breadth o claims

Having decided what to patent, the

next consideration is the breadth of

the claims. The claims must cover your

Patenting Value

Dr Lee Chapman o J.A. Kemp & Co.

introduced some o the key patentingissues to consider when he spoke at the

Oxord Innovation Society Meeting


11/28


current and future commercial interests

and those of your competitors. However,

it is necessary to balance monopoly with

patentability. The scope of the claims

determines what others cannot do, but

broad claims will attract more prior

art (i.e. are more likely to lack novelty

or be obvious) and will cover more

embodiments (that must be enabled by

the patents disclosure).

When to patent?

A patent application can be led

once you have at least one piece of

experimental data supporting theinvention. The more data the better, but

it is worth bearing in mind that some

countries allow you to le additional

data in support of technical effects

disclosed in the patent application

later. It is also important to ensure

that you do not shoot yourself in the

foot by waiting for more data and

accidentally disclosing the invention in

a non-condential manner before your

application is led because your own

disclosure will be citable against yourapplication in most countries.

Where to patent?

There are lots of issues to consider

in relation to where to le a patent

application. The key questions are:

What is the subject matter of the

invention?

What are the aims of the company?

What is the purpose of the patent ap-

plication?

Where are you based and where do

you trade?

Where are your competitors based

and where do they trade?

Where can the patent be enforced?

How much will it cost to le patent

applications in the different countries

of interest?

The subject matter of the invention

is important. Different countries have

different laws. For instance, methods of

diagnosis are not patentable in China

irrespective of how they are performed.

Also, it is important to be sensitive to

local customs or beliefs, particularly if

you wish to trade in a particular country.

The aims of the company and the

purpose of the patent applicationare interlinked. If you make and sell

products and the purpose of the patent

application(s) is to protect the product,

then you should le the application(s) in

those countries in which you make and

sell the products. Patent applications

should also be led in those countries in

which your competitors are based and

trade if you wish to prevent them from

using the invention or wish them to

obtain a licence. If your aim is to attract

investors and generate revenue frompatent applications, then applications

should be led in the countries of most

value. Such countries are invariably

those countries in which you and your

competitors are based and trade.


contact:

Dr Lee Chapman

J.A. Kemp & Co.T +44 (0)1865 406100

E [email protected]


12/28


Monitoring the power delivered

by a shaft is an important part of

understanding its performance. From

the initial validation that the system

is operating as designed through to

condition monitoring for improved

reliability and efciency, accurate

measurements of shaft torque are

vital. Unfortunately, this is easier said

than done. In instances where the

shaft must have high torsional rigidity,

in particular, the standard approach

of attaching strain gauges directly

to the shaft is unreliable. The twist

experienced by the strain gauge is

simply too small perhaps as small

as 0.001! Now, an Oxford inventor

has found a solution to the problem

of reliably measuring torque in low

strain applications a mechanical

shaft torque amplier which offers

a number of advantages over the

traditional approach.

It is expected that this new monitoring

technique will be of interest to

suppliers already active in the torquemeasurement eld and to end user

organisations working with low

strain (i.e. high torsional stiffness)

applications such as shafts that

connect large industrial gas or steam

turbines to electrical generators.

These are designed to be very stiff to

provide an extended life even if the

shaft is exposed to increased stress.

Improved torque measurement in this

environment results in reduced risk of

component failure and unscheduled

downtime.

Amplifer advantages

By applying a strain amplier

technique, users of the Oxford

invention can benet from improved

torque monitoring performance. Where

conventional strain gauges with a

gauge length in the range 3mm to

6mm may struggle to achieve 5% to

10% accuracy, strain amplication

can achieve accuracies of the order of

0.1%. Furthermore, compact bolt-on

packaging provides a retro-t solution

for existing installations and enables

improved measurement without

modifying the shaft or compromisingits performance. In one conguration,

the invention needs only 150mm of

shaft length for installation and can be

Sti challenge

Dr Andy Robertson introduces an

approach to measuring shat torque inlow strain conditions which will provide

improved measurement accuracy or the

power generation sector and many other

industries.

In instances where the shaft must have high

torsional rigidity the standard approach of

attaching strain gauges directly to the shaft is

unreliable.


13/28


tted, replaced or removed in a matter

of minutes without access to the ends

of the shaft.

With the amplier, torque measuring

equipment can be calibrated away

from the shaft to minimise downtime.

This lab-based calibration can be

undertaken at lower torques using

standard test equipment and caninclude temperature compensation

if appropriate. Improved signal-to-

noise ratio also makes measurement

possible in environments where

electrical noise sometimes prevents

standard torque monitoring.

Measurement accuracy will generally

be improved where best practice noise

reduction methods are also employed.

The device can be integrated with

signal conditioning and data transfer

telemetry to provide a complete torque

monitoring package. Depending on

the application, the packaged solution

can optionally contain an on-board

power supply and thermocouple for

operating temperature compensation.

(Useful in the harsh environments

encountered in a number of the target

applications.)

Who needs this solution?

Whether measured torque is seen as astandalone performance characteristic

or as an element in a comprehensive

condition monitoring system, the

amplier provides a valuable addition

to the users toolkit. Torque monitoring

is used in a wide range of industries

including power generation, marine,

aerospace and automotive.

Patent protection

This work is the subject of a UK patent

application and Isis welcomes interest

from companies interested in licensing

the technology.


contact:

Dr Andy Robertson

Technology Transfer ManagerIsis Innovation

T +44 (0)1865 280931

E [email protected]

Ref: 7935

Improved torque

measurement in this

environment results

in reduced risk of

component failure and

unscheduled downtime.

Loosely speaking, torque is a measure of the

turning force on an object.


14/28


Brain cancer is inherently serious and

life-threatening. More than 9,000

people in the UK were diagnosed

with brain or central nervous system

tumours in 2008, causing more

than 4,500 deaths. The brain is well

protected by the skull and so detection

usually only occurs in advanced stages

when the presence of the tumour has

caused unexplained symptoms. Now,

Oxford researchers are hopeful that

a new method will allow for earlier

detection.

Cancer spread

Metastasis, where there is a spread of

the cancer from one organ to another

part of the body, is one of the greatest

hurdles in cancer therapy. Between

20 and 40 percent of all cancer

patients will suffer metastatic spread

of the primary cancer to the brain.

Unfortunately, our inability to diagnose

brain metastasis (BM) early enough

and to obtain an accurate measure

of the number of metastases presentis a major limitation in the treatment

and management of cancer patients.

Clinical diagnosis of BM is limited to

larger, late-stage metastases (>5mm)

and early detection (


15/28


Cytokines only induce breakdown of

the blood-brain barrier local to tu-

mour sites. This enables these sites

to be imaged by MRI with contrast

agents that are normally excluded

from the brain.

There is no effect on normal vascu-

lature, the effect being specic to

tumour vasculature.

Market readiness

The Oxford research ndings have all

been achieved at much lower systemic

doses than previously used to treat

peripheral tumours and the BBB

returns to normal on discontinuation

of cytokine treatment.

The patent application covering

the invention has recently been

published: WO2011/070358 Systemic

administration of an agent that

permeabilises tumour vasculature.

Image: Breakdown of blood-brain

barrier


contact:

Dr Martin Procter, Senior


T +44 (0)1865 280919

E [email protected]

Ref: 6855

A low dose of cytokine temporarily increases

permeability, improving the delivery of agents that

can detect brain tumours.

Secondary brain cancer, MRI scan


16/28


Oxfords In-Line Flow Control Device is

an elegant solution to a longstanding

problem of complex, bulky and fragile

valve installations. The patent pending

design is now available to licence toproduct developers for any gas and

uid handling systems.

Pressure regulators are used for

uid and gas ow control in pipe

systems and conduits. Applications

are numerous and include the control

of shop air in industrial applications,

process uids in industrial plants,

transmission pipelines carrying water,

oil or gas, heating and refrigeration

systems, and many more. With somany uses in industrial and domestic

applications pressure regulators are

manufactured and distributed in very

high volumes worldwide.

Despite their widespread use, the

predominant design of most regulator

valves has a number of deciencies.

Large protruding parts, which are

exposed to the environment, make

the assembly bulky and create

installation challenges. The new designdeveloped in the Thermo-uids Lab of

the University of Oxfords Engineering

Department offers a valve that can

be entirely contained inside the pipe

carrying the gas or liquid that is being

regulated. With only a single moving

part this elegant design creates a

decisive improvement over existing

designs.

Oxfords In-line Flow Control Device

can be used as a pilot operatedpressure regulator or as a pressure

reducing ow device that maintains an

output pressure to a specic fraction

of the input pressure. The elds of

application are numerous as the device

is applicable to almost any mass ow

rate and pressure from very low to

Pressure point

Oxords new In-line Flow Control Device

will reduce costs, make installationdramatically easier and increase reliability

in all pipework systems, as Evert Geurtsen

explains.

can be retro-tted into existing

pipe-work without plant modi-

cations

ts inside the ow conduit,

requiring no additional space or

protrusions from the conduit

does not require its own certi-

ed pressure housing when tted

inside the existing, already certi-

ed, pipe-work

has very low manufacturing cost

in comparison to conventional

devices

can be produced and supplied

inside a standard length of pipe,

further facilitating storage, sup-

ply and installation

has only a single moving part

and no deformable or elastic

parts, resulting in high reliability

and low maintenance costs

is fully protected from the envi-

ronment

can cope with very high mass

ows

can control from low (Pa) to ultra

high pressure (MPa) ows

has good adjustment for mass

ow rate changes or pressure

drops

is scalable to any size

In application, Oxfords In-line Flow Control Device:


17/28


extremely high, e.g. from communal

gas supply systems to deep sea oil

exploration. The invention delivers

better than order-of-magnitude cost

savings in manufacture.

A prototype has been built and has an

excellent record of reliable operation

over an extended period of time in a

real world industrial application. The

technology has been demonstrated

to Technology Readiness Level 7 and

a patent application has been led.

Oxfords Engineering Department have

developed a numerical model that can

predict the valves dynamic behaviour

in use.

For the producers of regulator valves

this is a great opportunity to introduce

a new product range with genuine

differentiation and tangible advantages

for installers and operators.

Isis Innovation is interested in

meeting with companies that wish

to bid for opportunities to brand

and commercialise this remarkable

invention, with particular interest in

companies able to offer a rapid route

to market in high volume applications.


contact:

Evert Geurtsen

Technology Transfer Team LeaderIsis Innovation

T +44 (0)1865 614424

E [email protected]

Ref: 4220

A prototype has been

built and has an

excellent record of

reliable operation over

an extended period

of time in a real world

industrial application.


18/28


An Oxford invention, named the U-turn

Protocol, uses nonlinear dynamical

phenomena to investigate biological

cell system instability, including

cardiac cells. These phenomena

are important initiators of electrical

instabilities, therefore the method

can reveal potentially dangerous

arrhythmogenic regimes that are not

detectable using traditional protocols.

The invention can be practised with

current heart arrhythmia equipment

and is suitable for use in laboratoryconditions for screening single cells

to large numbers of cells or organs in

vitro or in vivo, as well as in clinical

settings.

Advantages o the U-turnProtocol

This new screening system promises

new opportunities for discovering safe

and antiarrhythmic drugs, offering

more reliable prediction of potentially

dangerous arrhythmogenic regimes,

improved assessment and earlier

prediction of the appearance of cardiac

instabilities.

In addition, the U-turn protocol may

accelerate research and developmentof new drugs by revealing hidden

proarrhythmic effects during early

pre-clinical studies, thereby reducing

drug discovery and development

costs.

Patent position

A PCT patent application has

been made (Publication No. WO

2011/121307), covering methods and

apparatus that use nonlinear dynamicsto assess the proarrhythmic effects of

drugs and heart arrhythmogenicity.

Isis would like to talk to companies

that are interested in developing this

technology.

Compelling rhythms

Existing antiarrhythmic drugs have

proved only moderately eective andcan produce adverse, lie-threatening

eects. Oxords U-turn Protocol reveals

potentially dangerous arrhythmogenic

regimes undetectable using traditional

methods. By Dr Natasha Tian.

The Oxford tool may:

Enhance the effectiveness of

antiarrhythmic drug therapy

by discerning the underlying

mechanism of arrhythmia,

which may suggest a more

suitable drug.

Re-evaluate already-marketed

drugs in terms of their effect

on cardiac dynamics and also

correct the dose medications.

Aid decision-making efforts in

the selection and developmentof new drugs and help to as-

sess the risk/benet ratio of a

given drug.

U-Turn Protocol potential


contact:

Dr Natasha Tian

Technology Transfer MangerIsis Innovation

T +44 (0)1865 280844

E [email protected]

Ref: 4315

Cardiolog

y

focu

s


19/28


Merely increasing dietary creatine

without also modulating creatine

transporter activity is ineffective

in tackling cardiovascular diseases.

Using a cell-based screening method,

Oxford academics have now identied

promising therapeutic compounds that

upregulate the creatine transporter.

This allows for the potential

treatment or prevention of ischaemia,

reperfusion injury, coronary heart

disease, heart attacks and angina.

Therapeutic potential

Treatment prior to cardiac surgery

Treatment as secondary protection

for patients at high risk of myocar-

dial ischaemia and infarction

Prolonged treatment of angina

Treatment of heart failure, particu-

larly in combination therapy

Protection of donor hearts prior to

transplant

Treatment of analagous brain condi-

tions

Ischaemic damage

Elevating intracellular creatine

prevents ischaemic damage from

occurring by boosting cardiac energy

reserves. In contrast, current

therapies aim to correct ischaemic

damage after it has occurred. Raising

creatine levels represents a new

therapeutic strategy that can be used

alone or in combination with existing

drugs with very different mechanisms

of action, such as altering blood

ow or the frequency and force of

contraction. A further advantage may

be that short-term dosing is likely

to have an effect lasting for several

months.

Supporting data

Therapeutic agent screens for small

molecules that upregulate the creatine

transporter have produced several

leads that are being followed up and

the academics have elucidated the

precise mechanism of action through

which creatine exerts its effects.

Pre-clinical work is currently ongoingto determine the benets of increasing

intracellular creatine in heart failure

in combination with other metabolic

therapies.

Patent protection

An international patent application

has been made (Publication No: WO

2011/058364). Isis would like to talk

to companies that are interested in

developing this technology.

Conronting cardio

disease

Oxord researchers have developed

methods or preventing and treating

cardiovascular diseases by modestly

increasing intracellular creatine in the

heart, as Dr Natasha Tian explains.


contact:

Dr Natasha Tian

Technology Transfer MangerIsis Innovation

T +44 (0)1865 280844

E [email protected]

Ref: 4222

Card

iology

focu

s


20/28


Researchers from the University of

Oxford have developed a portable digital

stethoscope and a phone application

(for low-spec and high-spec phones).

It enables basically trained healthcare

workers to capture high quality

phonocardiograms (PCGs) and transmitthem to a central server for analysis

and diagnosis by a trained expert. The

technology also offers signal quality

feedback. Electronic stethoscopes

available within the marketplace do not

offer these advantages.

Remote healthcare

Within both developing and developed

countries there is a growing

requirement for effective remote

monitoring of patients. Within the

UK, for instance, the NHS faces major

nancial challenges and reform which

will see healthcare delivery shifting

into the local community to reduce

hospital administration and the use

of beds. In developing countries such

as South Africa and India a large

percentage of the population live

within rural areas where constant

monitoring and hospital access is

difcult and expensive.

Remote healthcare workers have

been employed in such areas to aid in

alleviating some of these problems.

Low cost, easy to use medical devices

which allow for early, constant

monitoring and analysis by a doctor

hundreds of miles away are in global

demand.

Early diagnosis

The device was initially developed

to target tuberculosis pericarditis,

which affects around 10% of all TB

patients and has a high mortality rate

(40%) because sufferers in developing

countries struggle to reach a clinic

before it is too late. The ability to

pick up the early warning signs of this

and many other conditions is made

possible through the Oxford invention.

In the future it could also be utilised

for pulmonary auscultations and foetal

heart sound examinations.

Clinical trials

A clinical trial was conducted in Cape

Town, South Africa. Data from this

study has not yet been published.

Isis would like to speak to companies

interested in reviewing this data in

order to license and/or develop this

technology.

Stethoscope solution

Dr Bharti Ranavaya reveals a stethoscope

and phone application which recordsphonocardiograms and enables remote

monitoring o heart rates and murmurs.


contact:

Dr Bharti Ranavaya


T +44 (0)1865 280909

E [email protected]

Ref: 7159

The PCGs can be

transmitted to a central

server for analysis and

diagnosis by a trained

expert.

Cardiolog

y

focu

s


21/28


High-resolution bacterial

characterisation is essential in

microbiology, particularly for disease

diagnosis, where rapid and precise

identication is a high priority.

Gene-based methods have become

increasingly important in bacterialclassication, complementing and to

an extent replacing more traditional

phenotypic methods. However, until

now, there has been no single system

which works for all bacteria.

Scientists at the University of

Oxford have developed a universal

identication scheme based on

ribosomal multilocus sequence

typing (rMLST). This represents

the rst genotypic scheme that can

provide both broad and accurate

characterisation of bacteria at all

phylogenetic levels. The system works

through the identication and analysis

of allelic variation within the ribosomal

protein subunit (rps) genes, which are

universal yet record a wide range of

evolutionary diversity, to effect rapid

and highly accurate phylogenetic

identication.

Benefts o the Oxord system

Reliable identication

High resolution

Results at push of a button

One system for all bacteria

Supporting data

A web-accessible and expandable

database comprising genome data

from more than 2000 bacterial isolates

has been generated. The variation

of 53 rps genes is catalogued inthis database, providing a means

of dening the precise phylogenetic

position of any bacterial sequence

at the domain, phylum, class, order,

family, genus, species and strain

levels.

Applications

The data generated for the rMLST

scheme could be used in combination

with next generation sequencing

to enable the rapid identication of

bacterial isolates at the push of a

button. Equally the database enables

the development of PCR-based species

or strain-specic diagnostic tests.

Applications include:

Population studies

Epidemiological investigations

Diagnostic tests

Bacterial breakthrough

Dr Matthew Carpenter reports on the

frst gene-based bacterial identifcationsystem that can identiy all bacteria.


contact:

Dr Matthew Carpenter


T +44 (0)1865 280970

E [email protected]

Ref: 7895

A web-accessible and

expandable database

comprising genome

data from more than

2000 bacterial isolates

has been generated.


22/28


Sometimes known as optical wires,

glass optical bres are used for

transmitting light over long distances

with minimal loss, in much the same

way as a metallic wire transmits

electrons. Optical bres are widely

used in the telecommunication, sensor

and laser design sectors and there is

a market need to efciently couple

light into, or split light out of, these

bres. Oxford researchers have now

conceived a solution.

The working principle of the Oxford

method to couple light into or out of

the optical bre is based on a simple

notch coupler design (see diagram).A mirrored surface is fabricated at a

45 degree angle to the bre axis and

penetrates a desired distance into

the bre core. Virtually all of the light

directed in at the mirrored surface

from the side of the bre is coupled

into the bre core. The method

involves cutting an optical cable in half

and cutting a notch at a certain angle

in the corner of one of the exposed

ends. Using a specic chemical

process, aluminium is deposited just

on this corner in order to create a

discrete mirror. Reattaching the two

cable ends creates an entrance and

exit point in the optical bre for light

to be directed in or out. The academics

have now perfected this low-cost and

simple process to control the angle,

cross-section area and mirror coating

quality of the notch.

Advantages

Expands the range of bre couplers

and splitters to encompass any de-

sired coupling/splitting ratio.

Functions over a broad range ofwavelengths, so bandwidth is im-

proved in relation to couplers that

only work at a particular wave-

length.

Efcient method to monitor laser

spectroscopy equipment, by splitting

out only a small percentage of the

beam.

Economical process to introduce a

pump beam into bre lasers.

Let there be light

Dr Jon Carr looks at an inexpensive methodor the abrication o a microstructure which

allows light to be efciently coupled into or

split out o the side o an optical fbre.

Despite their many advantages

(capacity, unaffected by

electromagnetic interference

etc.) deployment of optical bre

technology has traditionally

been held back by difculties in

achieving connections that are

reliable, efcient and cost-effective.

A wide variety of connectordesigns have been developed for

different markets, most of which

are substantially more complex

than equivalents for cable and wire

technology.

Specialist splicing equipment

required for connections in an

optical cable can jeopardise the

integrity of the original connection.

The inexpensive and efcient

method described here offersthe potential for much simpler

connections to tap signals into and

out of optical bre cables.

Optical fbre technology


23/28


Novel application

Fibre-loop cavity ring-down

spectroscopy, developed for real-time

detection in micro uidics, demands

high coupling efciency. The Oxford

method ensures nearly all of the light

can be coupled into the bre loop, with

losses of less than a few percent. This

represents an improvement of some

magnitude over current technology.

Optical fbres

An optical bre typically consists

of a doped silica core and cladding

surrounded by a plastic buffer, whichprovides mechanical strength. The

doping ratio is tuned so that the

cladding has a lower refractive index

than the core. Incident light is then

trapped in the core by total internal

reection and the bre acts as a

waveguide.

Patent protection

This technology is now the subject of a

patent application, and Isis would like

to discuss with interested companies

the licensing of the technology.

Image: Bundle of optical bres

conducting light


contact:

Dr Jon Carr


T +44 (0)1865 280907

E [email protected]

Ref: 7989

The Oxford method

ensures nearly all

of the light can becoupled into the bre

loop, with losses

of less than a few

percent.

The academics have now perfected this low-costand simple process to control the angle, cross-

section area and mirror coating quality of the notch.

Mirrored notch acting as both an input and output coupler.

LIGHT IN

LIGHT OUT


24/28


Researchers at Oxford are helping

to build a future where autonomous

vehicles will play an important part

in all our lives and OUC is helping

support the application of this research

expertise by managing the consultancy

of Professor Paul Newman and some

of his colleagues in the Oxford Mobile

Robotics Group.

Robots will come in a variety of

shapes and sizes and undertake a

diverse set of tasks on our behalf,

says Professor Newman. We will want

them to carry things and transport us,

labour for us and defend us. We shall

want them to be exible, reliable and

safe. And they will need to work in a

range of environments, sometimes

hostile, and sometimes dynamically

changing.

Robots today already carry goods

around factories, move stock around

warehouses and manage our ports,

but these are constrained, controlled

No-hands navigation

Andrew Go, Head o Oxord UniversityConsulting (OUC), introduces an exciting

autonomous navigation innovation rom

the Oxord Mobile Robotics Group.

The Oxford approach allowscomputers in robots to interpret

data from sensors like cameras,

radars and lasers, aerial photos and

on-the-y internet queries.


25/28


and highly managed workspaces. In

such environments the navigation task

is made simple by installing reective

beacons or guide wires. However,

Professor Newman and his co-workers

are extending the reach of robot

navigation to truly vast scales without

the need for such expensive, awkward

and inconvenient modications of the

environment. Their approach does not

rely on GPS which, if available, does

not offer the accuracy required for

robots to make decisions about how

and when to move safely. Even if itdid, it would say nothing about what

is situated around the robot, and that

has a massive impact on autonomous

decision-making.

Instead, the Oxford approach is to

use the mathematics of probability

and estimation to allow computers in

robots to interpret data from sensors

like cameras, radars and lasers, aerial

photos and on-the-y internet queries.

Professor Newman uses machine

learning techniques to build and

calibrate mathematical models which

can explain the robots view of the

world in terms of prior experience

(training), prior knowledge (aerial

images, road plans and semantics)

and automatically generated web

queries. His goal is to produce

technology which allows robots to

always know precisely where they are

and what is around them.

One of Professor Newmans most

high prole projects to date is the

Wildcat vehicle (see images), a fully

autonomous road vehicle based on

a Bowler Wildcat. With research

supported by the Engineering and

Physical Sciences Research Council

(EPSRC), and in collaboration with

BAE Systems and Nissan, it is among

the rst projects in the world to

tackle the big challenges of creating

an autonomous vehicle that cango anywhere and deal with all the

situations it might encounter on the

open road.

The technology installed in the Wildcat

is set to remove the dependence on

GPS, improve navigation precision,

lower emissions, interpret local trafc

conditions, track risks, and above all

offer a hands-free experience to the

driver. All this by interpreting a ood

of data from sensors such as cameras,

radars, and lasers mounted on the car

itself.

But the application of Oxford mobile

robotics expertise is not only conned

to terrestial environments. GuidanceNavigation Limited (GNL), a leading

developer and supplier of sophisticated

navigation and position measurement

technologies, is also working with

Professor Newman to develop better

dynamic positioning systems for

offshore marine applications. GNLs

aim is to increase the exibility of

marine vessel operation, helping to

widen the weather operation window

and improve safety.

Lifelong infrastructure-free navigation

lies at the heart of the agenda for

The Oxford Mobile Robotics Group,

says Professor Newman. This is an

information engineering problem

encompassing lifelong learning, multi

sensor fusion, perception, control,

planning, state estimation and

software engineering. These skills

may be available to organisations

through OUC.

Organisations looking to access suchexpertise are invited to contact Oxford

University Consulting.


contact:

Andrew Goff

Head of OUCIsis Innovation

T +44 (0)1865 280866

E [email protected]

Ref: 7911


26/28


Isis Enterprise recently undertook

an extensive, seven month review of

a portfolio of patents owned by theKennedy Trust, an independent charity

supporting research into the causes

and treatment of rheumatic diseases.

The Trust funds the Kennedy Institute

one of the worlds leading research

centres in rheumatology which has

recently relocated to the University

of Oxford. Isis Enterprise was chosen

for this project on the basis of Isis

Innovations impeccable track record

of commercialising hundreds of

patents in a cost effective manner

over many years.

As a patient-centric organisation

operating in the fast-evolving eld

of biomedical research, the Trusts

patents were led at different points

in time over the past ten years. Most

comprised of method-of-treatment andprocess claims surrounding the use of

tumour necrosis factor (TNF) inhibitors

for new therapeutic indications and

treatment settings.

The Trusts management believed that

the patents held signicant potential

for translation into better clinical

outcomes for patients, and wanted to

Optimising IP Portolios

Gaurav Misra illustrates the importance

o understanding return-on-investmentrom intellectual property within research

organisations by looking at the work

undertaken by Isis Enterprise or the

Kennedy Trust.

Understanding the

commercial landscape

was key to unlocking the

portfolio value.

A major breakthrough in

understanding autoimmune

diseases occurred in the early

1990s, when immunologist

Professor Sir Marc Feldmann of

the Kennedy Institute in London,

England, discovered that the key

lay in molecules responsible for cell

communication molecules known

as cytokines. In the early 90s,

tests in humanoid mice revealed

that all the different cytokinescould be stopped by blocking one

kind namely Tumor Necrosis

Factor (TNF)-alpha.

Soon after Professor Feldmann

conducted the rst series of

successful trials with rheumatoid

arthritis patients at the Kennedy

Institute. During the test runs,

patients received a TNF-alpha-

specic monoclonal antibody

known as cA2, later registered as

iniximab.

Subsequently

this approach has

revolutionised

medical practice,

in recognition of

which Professor

Sir Feldmann

received theLifetime Achievement Award from

the EPO in 2007.


27/28


prioritise the portfolio on the basis of

such clinical value. Further, we were

to explore options for monetisation

or collaborative R&D to increase the

trusts research scope and budgets.

A secondary objective was to reduce

maintenance expenditure on these

patent positions, where possible,

without jeopardising their inherent

therapeutic potential.

Our task involved many challenges.

The rst was to gain a clear picture

of the portfolio by tracing the legal

status, approval timeline and litigation

history for each patent. The second

was to forecast the maintenance cost

of the patent positions till expiry, so

as to understand the nancial needs

and identify patent families with

high resource utilisation. Through

examining various patent databases

and detailed communication with

patent attorneys, these objectives

were achieved.

The next goal was to understand the

scientic objectives of the inventor

at the time the patent was rst led,

and to assess whether the logic was

still valid in the context of todays

commercial realities. Key issues

included the inventions industrialapplication, the clinical research

needed to translate it into a product,

along with the associated costs and

probabilities.

Blockbuster therapies

An understanding of the commercial

landscape was the key to unlocking

the value within the portfolio. The

Institutes pioneering work had found

global application via category-

leading blockbuster therapies

such as iniximab, adalimumab,

etanercept, and certolizumab. This

group of TNF inhibitors are the rst

monoclonal antibody therapies to

approach patent expiry, unleashing a

wave of conicting incentives across

the industry. Original branded

biologics are reliant on second

generation method and process

patents to extend market exclusivity,

which biosimilar manufacturers

are seeking to invalidate. Stakesare high because the foundational

regulatory mechanisms for new-age

biosimilar therapies will be decided

on the case of TNF inhibitors. Any

recommendations made to the Trust

had to be mindful of the partnering

landscape created by such industry

events.

The assessment of barriers to

entry also uncovered interesting

learning points. For example, a

distinction often had to be made

between the legal enforceability

of a patent (i.e. an inventive step

with industrial application) and its

market enforceability (i.e. the ability

to generate revenues based on the

claims).

The seven-month exercise enabled

Isis Enterprise to prioritise the whole

portfolio of over 100 patents and

for further research and licensing.

The resultant consolidation of theportfolio may even confer a signicant

cost-saving to the Trust, without

compromising the therapeutic

potential of the IP assets.

Image: Monoclonal antibodies


contact:

Gaurav Misra

Senior ConsultantIsis Enterprise

T +44(0)1865 280859

E [email protected]

Ref: 8138

Isis Enterprise helps technology providers and

seekers to source, develop and commercialise newinnovations.

An IP timeline

Patent portfolios of

successful research-

based organisations

grow with time. While

an organisations

strategy and priorities

may change, the

patent portfolio tends

to accrue and can

resemble a log book

of the organisations

research endeavours.

Over time, shifts

in the competitive

landscape add value

to some patents and

devalue others, while

the cost of maintaining

large IP portfolios

escalates sharply.


28/28

Forthcoming meetings of the Oxford Innovation Society will be held on the following dates:Thursday 22 March 2012 Thursday 20 September 2012 Thursday 6 December 2012

Meetings are held in Oxford for OIS members and invited guests, and are followed by a formalreception and dinner in an Oxford college hall.

Oxford Innovation Society

Isis Innovation Limited, Ewert House, Ewert Place, Summertown, Oxford OX2 7SG

T +44 (0)1865 280830 F +44 (0)1865 280831E [email protected] W isis-innovation.com

Isis Innovation Limited 2011

an intelligentpartnership

Andrew Davies

Corporate Director

Barclays Bank

T: 07775 548803

E: [email protected]

Nicola McConville

Partner - Technology Team

Blake Lapthorn

T: 01865 253284


Sue Staunton

Partner - Technology Group

James Cowper

T: 01865 200500


Providers of innovative banking, legal,accountancy and business advisorysolutions for technology basedbusinesses in Oxford and beyond.

Date post:	05-Apr-2018
Category:	Documents
Upload:	isis-innovation-ltd
View:	215 times
Download:	0 times

Isis Insights 67

Documents